Ganirelix Acetate
7 NDCs across 7 manufacturers|7 Generic,0 Brand
Ganirelix Acetate is used to treat ovarian hyperstimulation syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 29, 1999, and the first generic was approved Nov 30, 2018.
Ganirelix Acetate is available as 7 NDCs from 7 manufacturers (7 generic, 0 brand), with NADAC prices from $62.35 to $62.35 per ML. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
7
7G / 0B
Manufacturers
7
competing in market
Price Spread
$62.35 – $62.35
per ML
7d Activity
avg +0.0% WoW · of 7 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
7 manufacturers producing GANIRELIX ACETATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
FYREMADEL 250 MCG/0.5 ML SYR | $62.3467 per ML | — |
GANIRELIX ACET 250 MCG/0.5 ML | $62.3467 per ML | — |
Frequently Asked Questions
What is Ganirelix Acetate used to treat?
Ganirelix Acetate is used to treat ovarian hyperstimulation syndrome, per the National Library of Medicine's MED-RT classification.
When did Ganirelix Acetate become available as a generic?
FDA approved the first generic Ganirelix Acetate (ANDA) on Nov 30, 2018.
How many Ganirelix Acetate products are on the market?
The Ganirelix Acetate drug market contains 7 NDCs from 7 manufacturers — 7 generic and 0 brand products.
What is the price range for Ganirelix Acetate?
NADAC reference prices for Ganirelix Acetate range from $62.3467 to $62.3467 per ML.
Which manufacturers make Ganirelix Acetate?
7 manufacturers list Ganirelix Acetate in NADAC. Ranked by number of NDCs, the largest are Organon LLC (1), Lupin Pharmaceuticals Inc. (1), Fresenius Kabi USA, LLC (1), Meitheal Pharmaceuticals Inc. (1), Mullan Pharmaceutical Inc. (1).